Foro Mieloma Multiple

Current treatments
Evaluation of low-dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation.
http://www.ncbi.nlm.nih.gov/pubmed/26531225


Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible.
http://www.ncbi.nlm.nih.gov/pubmed/26518211


Lancet Oncol. 2015 Nov 16.t]
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
http://www.ncbi.nlm.nih.gov/pubmed/26596670


Curr Opin Hematol. 2015 Nov 7.
Plerixafor for stem cell mobilization: the current status.
http://www.ncbi.nlm.nih.gov/pubmed/26554889


Eur J Haematol. 2015 Nov 21.
Salvage therapy with pegylated liposomial doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al.
http://www.ncbi.nlm.nih.gov/pubmed/26589779